DESTINA Genomics Ltd. is a biotech company founded in Edinburgh in 2011 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley. In July 2012, it was created the Spanish subsidiary DESTINA Genomica S.L. with the goal to accelerate a long-term growth plan. The company is focused on the application and validation of its patented state-of-the-art technologies. DESTINA has created a unique and reliable chemistry for highly specific detection of nucleic acids. It can be used to identify any known target nucleic acid sequence, and in particular can directly detect small RNAs, without the multiple steps required by current methods. DESTINA mission is to become a leading manufacturer and supplier of custom chemical reagents and technologies for ‘best in class’ nucleic acid based biomarker assays. DESTINA’s technology introduces cheaper, more accurate and much more meaningful Nucleic Acid Testing tools.